Medical Affairs Reputations (EU5) [PsO]
Compare 10 psoriasis medical affairs teams. See how your team stacks up to the market leader
In the EU5, several of the psoriasis medical affairs teams we surveyed are running neck and neck with at least one rival. The 150 dermatologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put your team ahead of the competition?”
Discover all the ways you can improve your medical affair services in Medical Affairs Reputations: Psoriasis (EU5). Purchase your copy now
Comparing 10 major Psoriasis treatments from AbbVie, Biogen, Celgene, Eli Lilly, Janssen Cilag, Merck Sharp & Dohme, Napp/Mundipharma, Novartis, and Pfizer, this detailed report reveals
Top Takeaways
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 8 medical affairs teams—answering important questions like:
What do doctors need?
We surveyed 100 US dermatologists—chosen from the largest community of validated physicians in the world.
All respondents
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
In the EU5, several of the psoriasis medical affairs teams we surveyed are running neck and neck with at least one rival. The 150 dermatologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put your team ahead of the competition?”
Discover all the ways you can improve your medical affair services in Medical Affairs Reputations: Psoriasis (EU5). Purchase your copy now
Comparing 10 major Psoriasis treatments from AbbVie, Biogen, Celgene, Eli Lilly, Janssen Cilag, Merck Sharp & Dohme, Napp/Mundipharma, Novartis, and Pfizer, this detailed report reveals
- How dermatologists rate your team overall, and on 12 key medical affairs services
- Which medical affairs services are most important.
- How, and how often dermatologists want to meet with your team.
- What you can do to improve your medical affairs services.
Top Takeaways
- One team has a narrow lead: Rated for overall quality of interactions, the leading team is a full three points ahead. Farther down the pack there are tight races for 2nd and 4th place.
- Modest performance: Overall, scores are hovering just above neutral, but the top teams earned somewhat positive scores—especially in the areas important to doctors.
- Doctors are satisfied with some teams: The top teams tend to earn high satisfaction scores in every area, and are way ahead of the pack in areas important to doctors.
- Doctors rely on teams for a range of services: The most important medical affairs services relate to information provision, speaker programmes, and clinical trials.
- Active market: In the past six months, half of the teams interacted with more than 75% of doctors surveyed. The most active teams interacted with more than 90% of them.
- Doctors want to see teams in-person and not too often: The report reveals how, and how frequently your team should engage.
- Benepali (etanercept; Biogen)
- Cosentyx (secukinumab; Novartis)
- Enbrel (etanercept; Pfizer)
- Humira (adalimumab; AbbVie)
- Inflectra (infliximab; Pfizer)
- Otezla (apremilast; Celgene)
- Remicade (infliximab; Merck Sharp & Dohme)
- Remsima (infliximab; Napp/Mundipharma)
- Stelara (ustekinumab; Janssen Cilag)
- Taltz (ixekizumab; Eli Lilly)
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 8 medical affairs teams—answering important questions like:
What do doctors need?
- How, and how often are they using your medical affairs team?
- What services do they consider most important?
- How often should you contact them? What channels are best?
- How memorable are your team’s interactions with doctors?
- How do doctors rank your team for performance and satisfaction in 12 key areas?
- How does your team compare to the competition—in each area, and overall?
- Are you delivering the services that are most important to doctors?
- Where do you need to improve?
- How can your team enhance its services?
We surveyed 100 US dermatologists—chosen from the largest community of validated physicians in the world.
All respondents
- Have been practicing for between 3 and 35 years
- See at least 5 patients with psoriasis in a typical month
- Devote at least 50% of their time to direct patient care
- Have interacted with at least one listed product’s medical affairs team in the past 6 months.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1. OBJECTIVES, SURVEY METHODOLOGY AND SAMPLING, PRODUCTS INCLUDED IN THE SURVEY, EXECUTIVE SUMMARY
2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
4.1 Preferred interaction media and frequency, and suggestions for improvement
5. APPENDIX
2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
4.1 Preferred interaction media and frequency, and suggestions for improvement
5. APPENDIX
